Evidence map›Paper›PMID 42756129›Full record

ArticleFrontiers in immunology2026

Comparative immunogenicity and protective efficacy of BECC438 and BECC470 adjuvants in a vaccine formulation against

Prolay Halder, Debaki Ranjan Howlader, Satabdi Biswas, Risha Haldar, Suhrid Maiti, Sayan Das, Zackary K Dietz, Ti Lu, Sean K Whittier, Robert K Ernst and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Prolay HalderBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Debaki Ranjan HowladerBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Satabdi BiswasBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Risha HaldarBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Suhrid MaitiBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Sayan DasDepartment of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
Zackary K DietzBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Ti LuBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Sean K WhittierBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
William D PickingBond Life Sciences Center, University of Missouri, Columbia, MO, United States.
Wendy L PickingBond Life Sciences Center, University of Missouri, Columbia, MO, United States.

Funding

Vaccines to counter emerging antibiotic resistance (R01AI138970)R01AI138970 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2018 to 2022
$6.0M
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosaR01AI169781 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI Wendy L. Picking · 2023 to 2026
$3.1M
Development of a broadly protective subunit vaccine against Pseudomonas aeruginosaR21AI140701 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI PICKING, WENDY L. · 2018 to 2019
$427k
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosaR21AI164616 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2021 to 2022
$423k
NIAID NIH HHS HHSN272201800043CNIAID NIH HHS R01 AI138970NIAID NIH HHS R01 AI169781NIAID NIH HHS R21 AI140701NIAID NIH HHS R21 AI164616
6 · The paper itself

Abstract

The development of effective vaccines against the opportunistic pathogen

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineImmunogenicity, VaccineLipid APseudomonas aeruginosaPseudomonas InfectionsPseudomonas VaccinesAnimalsAntibodies, BacterialAntigens, BacterialBacterial ToxinsFemaleImmunoglobulin GMiceProtein Subunit VaccinesToll-Like Receptor AgonistsAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, BacterialAntigens, BacterialBacterial ToxinsImmunoglobulin GLipid AProtein Subunit VaccinesPseudomonas VaccinesToll-Like Receptor AgonistsVaccines, SubunitBECC438BECC470humoral immunityintramuscular immunizationintranasal immunizationmucosal immunityPseudomonas aeruginosavaccine adjuvants

Identifiers

PMID42756129
PMCPMC13582523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.